Impact of PREVENT-ASCVD vs pooled cohort equations on statin eligibility across demographic groups: Insights from the NIH All of Us Research Program
Journal of Clinical Lipidology · 2026-09 · 20 (9) · 2062-2068
DOI: 10.1016/j.jacl.2026.07.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026-09. Verfasst von Cammie Young und 3 weiteren Autor:innen. Beteiligte Einrichtung: From the Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division and Center for Global Cardiometabolic Health and Nutrition, Uni…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Demography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We compared the predicting risk of cardiovascular EVENTS-atherosclerotic cardiovascular disease (PREVENT-ASCVD) risk equation with the pooled cohort equation (PCE) for estimating statin eligibility across demographic subgroups in the All of Us Research Program in patients without ASCVD, heart failure, diabetes, or lipid-lowering therapy. Statin eligibility was defined as a 10-year ASCVD risk for PREVENT-ASCVD ≥5% and PCE ≥7.5%. Eligibility estimates were compared across age, sex, and race/ethnicity, and by quintile of polysocial risk score (PsRS). Among 25,188 participants, overall statin eligibility was 23.1% under PREVENT-ASCVD compared with 28.0% under PCE (Δ = 4.9%, P < 0.001). The largest differences were among participants aged 60 to 69 years and among Black participants. Among those with PsRS data (n = 6213), PREVENT-ASCVD estimated lower statin eligibility than PCE across all quintiles (P < 0.05). Differences in statin eligibility between PREVENT-ASCVD and PCE persist even when applying guideline-recommended thresholds, highlighting the importance of incorporating additional risk-enhancing factors beyond those included in either equation to better inform primary prevention decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- From the Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division and Center for Global Cardiometabolic Health and Nutrition, University of California, Irvine, United States.
- From the Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division and Center for Global Cardiometabolic Health and Nutrition, University of California, Irvine, United States. Electronic address: ndwo…
Zitieren
APA
Young, C., Golden, F., Fan, W., & Wong, N. D. (2026). Impact of PREVENT-ASCVD vs pooled cohort equations on statin eligibility across demographic groups: Insights from the NIH All of Us Research Program. Journal of Clinical Lipidology, 20(9), 2062-2068. https://doi.org/10.1016/j.jacl.2026.07.003
Vancouver
Young C, Golden F, Fan W, Wong ND. Impact of PREVENT-ASCVD vs pooled cohort equations on statin eligibility across demographic groups: Insights from the NIH All of Us Research Program. Journal of Clinical Lipidology. 2026;20(9):2062-2068. doi:10.1016/j.jacl.2026.07.003
BibTeX
@article{Young2026,
author = {Young, Cammie and Golden, Frances and Fan, Wenjun and Wong, Nathan D},
title = {Impact of PREVENT-ASCVD vs pooled cohort equations on statin eligibility across demographic groups: Insights from the NIH All of Us Research Program},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {9},
pages = {2062--2068},
doi = {10.1016/j.jacl.2026.07.003}
}
EUVIMED